Parkwalk closes Orthox investment

We are pleased to announce that Parkwalk VI, the Opportunities EIS Fund and the University of Oxford Isis Fund II have made an investment in Orthox,  a tissue regenerative orthopaedic implant company with technology spun out of Oxford University.

Orthox is a medical device company founded in 2008 to exploit FibroFix, a novel silk-based biomaterial platform, for the repair of injuries to cartilage and bone. FibroFix combines exceptional strength and resilience with a porous architecture and chemical structure similar to Fibronectin, an essential component of human cartilage. Orthox believes these properties will allow FibroFix™ to act as both an immediate functional replacement for damaged cartilage, and a long term regenerative repair solution.